PARP-1抑制剂作为^(131)I辅增敏剂在甲状腺癌治疗中的应用  

Utility of the PARP-1 inhibitor(PJ-34) combine with ^(131)I for thyroid cancer therapy

作　　者：刘泽明[1] 赵月[1] 李大鹏[1] 沈娜[1] 郭辉[1] 曾文[1] 赵向旺[1] 王龙强[1] 胡佳[1] 李治 刘春萍[1] 黄韬[1] 

机构地区：[1]华中科技大学同济医学院附属协和医院乳腺甲状腺外科中心,湖北武汉430022

出　　处：《中国现代普通外科进展》2013年第4期260-264,共5页Chinese Journal of Current Advances in General Surgery

摘　　要：目的:探讨131I照射以及联合PARP-1抑制剂(PJ-34)对于甲状腺癌细胞系BCPAP增殖与凋亡的影响。方法:常规培养人甲状腺癌细胞BCPAP,采用CCK-8法检测BCPAP的增殖、流式细胞术检测细胞凋亡,并用Western blot法检测Bcl-2、Bax的表达。结果:131I和PJ-34均能抑制BCPAP细胞的增殖,且与浓度呈相关性,而且两者联合作用比单独应用131I有更好的抑制效果。流式细胞术检测结果显示131I和PJ-34的联合作用比单独用131I有更高的凋亡率。Western blot结果显示随着131I中加入的PJ-34浓度的升高,Bax表达量逐渐升高,而Bcl-2的表达量呈降低趋势。结论:131I和PJ-34联合作用比单独应用131I对BCPAP有更好的抑制效果和更强的促凋亡作用,这为131I和PJ-34联合治疗甲状腺癌提供了初步的实验依据。Objective： To investigate the influence of ^131I combine with PARP-1 inhibitor （PJ-34） on the proliferation and apoptosis of BCPAP cells. Methods： The BCPAP cells were rou- tinely cultured, CCK-8 was used to analyze cell proliferation, apoptosis was assessed by flow cy tometry, the expression of Bcl-2 and Bax was detected by using Western blot. Results： The ^131I and P J-34 both suppressed the BCPAP CELLS correlated with the concentration, and ^131I combine with P J-34 could suppress the proliferation stronger than^131I does.^131I combine with P J-34 also have high apoptosis rate than ^131I does by flow cytometry, the western-blot illustrate that the ex- pression of Bax increased and the expression of Bcl-2 decreased with P J-34 exaltation in BCPAP cells of^131I. Conclusion： ^131I combine with P J-34 have better suppression and stronger apoptosis of BCPAP cells than only ^131I does. our study provided a preliminary evidence by using ^131I combination with P J-34 for thyroid cancer threatment.

关 键 词：甲状腺肿瘤 细胞增殖-细胞凋亡 ^131I pJ-34 

分 类 号：R736.1[医药卫生—肿瘤]